ClinicalTrials.gg
CompletedNCT03315702Updated Jul 25, 2019Results posted

Effect of Mechanical Ventilation on Plasma Concentration Level of R-spondin Proteins

An observational study in Acute Lung Injury, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-07-25.

Sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
52
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 59 studies in Acute Lung Injury with a site in China — 20 open to participants now, 20 under way, 1 of them phase 3. Acute Lung Injury · China.

Enrollment
18th of 28
52 · median 103
Started
2017
with 4 others
Observational
28 of 59
10 open now
Registered
16th of 59
by date
Lead sponsor
4 of 59
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Among the 59 studies in Acute Lung Injury with a site in China, this one is the 18th largest by enrollment of the 28 observational ones that give a count, is one of 5 that started in 2017, is one of 28 observational ones, and was the 16th registered.

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

Browse Acute Lung Injury studies →

Open to participants now

20 of the 59 studies in Acute Lung Injury with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Acute Lung Injury with a site in China, or all of them as a file.
02

Study summary

As novel agonists of Wnt/β-catenin signaling pathway, R-spondin proteins constitute a class of ligands, including R-spondin 1/2/3/4, functioning through their receptors leucine-rich repeat-containing G-protein coupled receptor (LGR)4/5/6 to enhance Wnt/β-catenin activity. Since Wnt signaling plays pivotal roles in the regulation of many life processes involved in embryogenesis and adulthood, R-spondin proteins also take part in cell proliferation, differentiation and morphogenesis.For example, in the formation of respiratory system,R-spondin 2 is required for normal laryngeal-tracheal and lung morphogenesis,and the lack of R-spondin 1 expression results in the absence of duct side-branching development and subsequent alveolar formation. In addition, R-spondins show protective effect in tissue injury and diseases. R-spondin 1 and R-spondin 3 have been reported to prevent chemotherapy- or radiotherapy-induced mucous membrane lesion. R-spondin 1 attenuates oral mucositis contributed by radiotherapy in mouse models and R-spondin 3 potentiates intestinal regeneration elicited via gastrointestinal toxic effect of chemoradiotherapy treatment. However, whether R-spondin proteins exert salient influence on acute lung injury especially induced by mechanical ventilation is deficient. Therefore, this study aims to ascertain the implication of R-spondin proteins in the pathology of mechanical ventilation induced lung injury through detecting human plasma concentration change of R-spondin 1/2/3/4 after mechanical ventilation and interference effects in mouse model, which is helpful for prevention and treatment of ventilation induced lung injury.

Read the detailed description

Mechanical ventilation is a critical intervention for patients with acute respiratory failure. However, lung overdistension induced by mechanical ventilation also causes pulmonary endothelial dysfunction. The injurious effect of mechanical stretch on pulmonary endothelium has been implicated in the development of ventilator-induced lung injury, which is characterized by pulmonary inflammation and particularly increased vascular permeability. In addition, the investigators and others have previously shown that mechanical stretch increases cultured lung endothelial monolayer permeability in vitro and promotes lung vascular permeability in mice Thus, elucidating the mechanisms underlying the mechanical stretch-induced lung endothelial barrier dysfunction may provide a novel clinical therapeutic target against ventilator-induced lung injury.

As novel agonists of Wnt/β-catenin signaling pathway, R-spondin proteins constitute a class of ligands, including R-spondin 1/2/3/4, functioning through their receptors leucine-rich repeat-containing G-protein coupled receptor (LGR)4/5/6 to enhance Wnt/β-catenin activity. Since Wnt signaling plays pivotal roles in the regulation of many life processes involved in embryogenesis and adulthood, R-spondin proteins also take part in cell proliferation, differentiation and morphogenesis. For example, in the formation of respiratory system,R-spondin 2 is required for normal laryngeal-tracheal and lung morphogenesis,and the lack of R-spondin 1 expression results in the absence of duct side-branching development and subsequent alveolar formation. In addition, R-spondins show protective effect in tissue injury and diseases. R-spondin 1 and R-spondin 3 have been reported to prevent chemotherapy- or radiotherapy-induced mucous membrane lesion. R-spondin 1 attenuates oral mucositis contributed by radiotherapy in mouse models and R-spondin 3 potentiates intestinal regeneration elicited via gastrointestinal toxic effect of chemoradiotherapy treatment. However, whether R-spondin proteins exert salient influence on acute lung injury especially induced by mechanical ventilation is deficient. Therefore, this study aims to ascertain the implication of R-spondin proteins in the pathology of mechanical ventilation induced lung injury through detecting human plasma concentration change of R-spondin 1/2/3/4 after mechanical ventilation and interference effects in mouse model, which is helpful for prevention and treatment of ventilation induced lung injury.

03

Conditions studied

  • Acute Lung Injury

Keywords

  • R-spondin proteins, mechanical ventilation, lung injury
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients undergo elective surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • undergo elective surgery with mechanical ventilation lasting for > 3 hours; classified as physical status I to III according to the Physical Status Classification System; Written is approved.

Exclusion criteria

Exclusion Criteria:

  • chronic lung disease; recent lung infection; recent anaesthetics or mechanical ventilation treatment; hemodilution with massive fluid supply during surgery; children;women during pregnancy or lactation; being involved in other clinical subjects
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
52 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • control/mechanical ventilation

    venous blood samples collected from patients twice,relatively before mechanical ventilation and 3rd hour after mechanical ventilation

    Other: mechanical ventilation

Interventions

  • Othermechanical ventilation

    mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cm H2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.

06

What researchers measure

Primary outcomes

  1. Change in Plasma Concentration of R-spondin 1

    The venous blood samples were collected twice for each patient that the first time was around the onset of the mechanical ventilation and the second was 3rd hour after the onset of the mechanical ventilation, which were named as sample A and sample B relatively. Then, plasmids were separated by centrifugation and detected for R-spondin1 concentration. And the outcome was calculated by subtracting the R-spondin1 plasmid concentration of sample A from the R-spondin1 plasmid concentration of sample B, which was the change in plasma concentration of R-spondin1.

    Time frame: 3 hours

  2. Change in Plasma Concentration of R-spondin 2

    The venous blood samples were collected twice for each patient that the first time was around the onset of the mechanical ventilation and the second was 3rd hour after the onset of the mechanical ventilation, which were named as sample A and sample B relatively. Then, plasmids were separated by centrifugation and detected for R-spondin2 concentration. And the outcome was calculated by subtracting the R-spondin2 plasmid concentration of sample A from the R-spondin2 plasmid concentration of sample B, which was the change in plasma concentration of R-spondin2.

    Time frame: 3 hours

  3. Change in Plasma Concentration of R-spondin3

    The venous blood samples were collected twice for each patient that the first time was around the onset of the mechanical ventilation and the second was 3rd hour after the onset of the mechanical ventilation, which were named as sample A and sample B relatively. Then, plasmids were separated by centrifugation and detected for R-spondin3 concentration. And the outcome was calculated by subtracting the R-spondin3 plasmid concentration of sample A from the R-spondin3 plasmid concentration of sample B, which was the change in plasma concentration of R-spondin3.

    Time frame: 3 hours

  4. Change in Plasma Concentration of R-spondin4

    The venous blood samples were collected twice for each patient that the first time was around the onset of the mechanical ventilation and the second was 3rd hour after the onset of the mechanical ventilation, which were named as sample A and sample B relatively. Then, plasmids were separated by centrifugation and detected for R-spondin4 concentration. And the outcome was calculated by subtracting the R-spondin4 plasmid concentration of sample A from the R-spondin4 plasmid concentration of sample B, which was the change in plasma concentration of R-spondin4.

    Time frame: 3 hours

07

Results

Posted Jul 25, 2019

Participant flow

Participant flow — Overall Study
MilestoneControl/Mechanical Ventilation
Started52
Completed52
Not completed0

Outcome measures

PrimaryChange in Plasma Concentration of R-spondin 1

The venous blood samples were collected twice for each patient that the first time was around the onset of the mechanical ventilation and the second was 3rd hour after the onset of the mechanical ventilation, which were named as sample A and sample B relatively. Then, plasmids were separated by centrifugation and detected for R-spondin1 concentration. And the outcome was calculated by subtracting the R-spondin1 plasmid concentration of sample A from the R-spondin1 plasmid concentration of sample B, which was the change in plasma concentration of R-spondin1.

Time frame:
3 hours
Reported as:
Mean · pg/ml
Change in Plasma Concentration of R-spondin 1
pg/mlControl/Mechanical Ventilation
Change in Plasma Concentration of R-spondin 11407.4080 ± 1350.7859
PrimaryChange in Plasma Concentration of R-spondin 2

The venous blood samples were collected twice for each patient that the first time was around the onset of the mechanical ventilation and the second was 3rd hour after the onset of the mechanical ventilation, which were named as sample A and sample B relatively. Then, plasmids were separated by centrifugation and detected for R-spondin2 concentration. And the outcome was calculated by subtracting the R-spondin2 plasmid concentration of sample A from the R-spondin2 plasmid concentration of sample B, which was the change in plasma concentration of R-spondin2.

Time frame:
3 hours
Reported as:
Mean · pg/ml
Change in Plasma Concentration of R-spondin 2
pg/mlControl/Mechanical Ventilation
Change in Plasma Concentration of R-spondin 2-2.1830 ± 35.3601
PrimaryChange in Plasma Concentration of R-spondin3

The venous blood samples were collected twice for each patient that the first time was around the onset of the mechanical ventilation and the second was 3rd hour after the onset of the mechanical ventilation, which were named as sample A and sample B relatively. Then, plasmids were separated by centrifugation and detected for R-spondin3 concentration. And the outcome was calculated by subtracting the R-spondin3 plasmid concentration of sample A from the R-spondin3 plasmid concentration of sample B, which was the change in plasma concentration of R-spondin3.

Time frame:
3 hours
Reported as:
Mean · pg/ml
Change in Plasma Concentration of R-spondin3
pg/mlControl/Mechanical Ventilation
Change in Plasma Concentration of R-spondin3-2.8956 ± 30.2781
PrimaryChange in Plasma Concentration of R-spondin4

The venous blood samples were collected twice for each patient that the first time was around the onset of the mechanical ventilation and the second was 3rd hour after the onset of the mechanical ventilation, which were named as sample A and sample B relatively. Then, plasmids were separated by centrifugation and detected for R-spondin4 concentration. And the outcome was calculated by subtracting the R-spondin4 plasmid concentration of sample A from the R-spondin4 plasmid concentration of sample B, which was the change in plasma concentration of R-spondin4.

Time frame:
3 hours
Reported as:
Mean · pg/ml
Change in Plasma Concentration of R-spondin4
pg/mlControl/Mechanical Ventilation
Change in Plasma Concentration of R-spondin4-269.8598 ± 1230.6612

Adverse events

Collected over 3 hours Explanation: The venous blood samples were collected twice for each patient that the first time was around the onset of the mechanical ventilation and the second was 3rd hour after the onset of the mechanical ventilation.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control/Mechanical Ventilation0/52 (0%)0/52 (0%)0/52 (0%)
Most frequent other events
Most frequent other events
EventControl/Mechanical Ventilation
0General disorders0/52

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Control/Mechanical Ventilation
<=18 years0
Between 18 and 65 years52
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Control/Mechanical Ventilation
Female14
Male38
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Control/Mechanical Ventilation
American Indian or Alaska Native0
Asian52
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Control/Mechanical Ventilation
China52
08

Study locations

1 site
  • Department of Anesthesia, Shanghai Xinhua hospital
    Shanghai, Shanghai 200082, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Oct 2017, 0 months.

Results were first posted in Jul 2019, 1 year 9 months after primary completion.

Of 41 non-industry observational studies under Acute Lung Injury, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's 0 months is below that.

Counting every sponsor, half of 46 studies reached it within 18 months; a quarter within 8 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2017
First posted
Oct 20, 2017
StartActual
Sep 22, 2017
Primary completionActual
Oct 15, 2017
CompletionActual
Oct 31, 2017
Results first posted
Jul 25, 2019
Last update
Jul 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03315702
Responsible party
Sponsor
First posted
Oct 20, 2017
Start date
Sep 22, 2017
Primary completion
Oct 15, 2017
Completion
Oct 31, 2017
Results posted
Jul 25, 2019
Last update
Jul 25, 2019

Study contacts

Lai Jiang, chief doctor
study chair · Xinhua Hospital affiliated to Medicine school,Shanghai Jiaotong University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion